Skip to main content
SpringerLink
Log in

Medikamente und ihre Wirkungsweisen

  • Chapter
Morbus Crohn - Colitis ulcerosa

  • 115 Accesses

Zusammenfassung

Die medikamentöse Therapie der chronisch-entzündlichen Darmerkrankungen beschränkt sich bis heute auf die Unterdrückung der Entzündungsaktivität, da Ätiologie und exakte Pathogenese nicht bekannt sind. Das allgemeine Wissen um die Regulation der Entzündungsreaktion hat in den letzten Jahren ganz entscheidend zugenommen. Dadurch wurde es möglich, die Wirkung antiinflammatorischer Substanzen, die über Jahre empirisch in der Therapie der chronisch-entzündlichen Darmerkrankungen eingesetzt wurden (Steroide, Salicylate), zu verstehen. Darüber hinaus wird der gezielte Einsatz weiterer Medikamente wie Immunsuppressiva pathophysiologisch begründbar.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Glukokortikoide

  • Löfberg R (1995) New steroids for inflammatory bowel disease. Inflamm Bow Dis 1: 135–141

    Article  Google Scholar 

  • Mulder CJJ, Tytgat GNJ (1993) Topical corticosteroids in inflammatory bowel disease. Aliment Pharmacol Ther 7: 125–130

    Article  PubMed  CAS  Google Scholar 

  • Sachar DB (1994) Budesonide for inflammatory bowel disease. Is it a magic bullet? N Engl J Med 331: 873–874

    CAS  Google Scholar 

  • Thomsen O, Andersen T, Langholz E et al. (1994) Lack of adrenal gland suppression with budesonide enema in active distal ulcerative Colitis: a prednisolone-controlled 8-week study. Eur J Gastroenterol Hepatol 6: 507–511

    Article  Google Scholar 

  • Tromm A, Möllmann HW, May B (1996) Praxis der Glukokortikoidtherapie chronisch entzündlicher Darmerkrankungen. In: May B, Möllmann HW (Hrsg) Glukokortikoidtherapie chronisch entzündlicher Darmerkrankungen. Falk Foundation e.V., Freiburg, S9–26

    Google Scholar 

Sulfasalazin und Aminosalizylate

  • Bachrach WH (1988) Sulfasalazine: A historical perspective. Am J Gastroenterol 83: 487–496

    PubMed  CAS  Google Scholar 

  • Christensen LA, Fallingborg J, Jacobsen BA et al. (1994) Comparative bioavailability of 5- aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 8: 289–294

    Article  PubMed  CAS  Google Scholar 

  • Clerici C, Gentiii G, Boschetti E et al. (1994) Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery. Dig Dis Sei 39: 2601–2606

    Article  CAS  Google Scholar 

  • Gaginella TS, Walsh RE (1992) Sulfasalazine - multiplicity of action. Dig Dis Sei 37: 801–812

    Article  CAS  Google Scholar 

  • Hanauer SB, Krawitt EL, Robinson M et al. (1993) Long-term management of Crohn’s disease with mesalamine capsules (Pentasa®). Am J Gastroenterol 88: 1343–1351

    PubMed  CAS  Google Scholar 

  • Layer PH, Goebell H, Keller J et al. (1995) Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 108: 1427–1433

    Article  PubMed  CAS  Google Scholar 

  • Sturgeon JB, Bhatia P, Hermens D et al. (1995) Exacerbation of chronic ulcerative Colitis with mesalamine. Gastroenterology 108: 1889–1893.

    Article  PubMed  CAS  Google Scholar 

  • Svartz N (1988) Some notes on the discovery and development of salsazopyrin. Am J Gastroenterol 83: 497–503

    PubMed  CAS  Google Scholar 

  • Wadworth AN, Fitton A (1991) Olsalazine. Drugs 4: 647–664

    Article  Google Scholar 

Nichtsteroidale Immunsuppressiva

  • Brynskov J (1993) Cyclosporin for inflammatory bowel disease: mechanisms and possible actions. Scand J Gastroenterol 28: 849–857.

    Article  PubMed  CAS  Google Scholar 

  • Connell WR, Kamm MA, Ritchie JK et al. (1993) Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34: 1081–1085

    Article  PubMed  CAS  Google Scholar 

  • Connell WR, Kamm MA, Dickson M et al. (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343: 1249–1252

    Article  PubMed  CAS  Google Scholar 

  • Hawthorne AB, Hawkey CJ (1989) Immunosuppressive drugs in inflammatory bowel disease. Drugs 38: 267–288

    Article  PubMed  CAS  Google Scholar 

  • Passfall J, Distler A, Riecken EO et al. (1992) Development of ulcerative Colitis under the immunosuppressive effect of cyclosporine. Clin Investig 70: 611–613.

    Article  PubMed  CAS  Google Scholar 

  • Present DH (1989) 6-mercaptopurine and other immunosuppressive agents in the treatment of Crohn’s disease and ulcerative Colitis. Gastroenterol Clin North Am 18: 57–69

    PubMed  CAS  Google Scholar 

  • Sandborn WJ (1995) A eritical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bow Dis 1: 48–63

    Article  Google Scholar 

  • Treem WR, Hyams JS (1994) Cyclosporine therapy for gastrointestinal disease. J Pediatr Gastroenterol Nutr 18: 270–278

    Article  PubMed  CAS  Google Scholar 

Metronidazol

  • Benjamin SH, Guarino J, Gordon SJ et al. (1987) Metronidazole: clinical experience in inflammatory bowel disease. Gastroenterology 92: 1314

    Google Scholar 

  • Duffy LF, Daum F, Fisher SE et al. (1985) Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterology 88: 681–684

    PubMed  CAS  Google Scholar 

  • Goldman P (1985) Metronidazole. N Engl J Med 303: 1212–1217

    Google Scholar 

  • Stahlberg D, Barany F, Einarsson K et al. (1991) Neurophysiologic studies of patients with Crohn’s disease on long-term treatment with metronidazole. Scand J Gastroenterol 26: 219– 224

    Article  PubMed  CAS  Google Scholar 

Potentielle Medikamente und Substanzen zur symptomatischen Therapie

  • Belluzzi A, Brignola C, Campieri M et al. (1994) Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn’s disease patients. Dig Dis Sei 39: 2589–2594

    Article  CAS  Google Scholar 

  • Bernstein CN, Shanahan F (1993) Factor XIII: Is it a factor in Crohn’s disease? Gastroenterology 105: 605–607

    PubMed  CAS  Google Scholar 

  • Cohen RD, Hanauer SB (1995) Immunotherapy agents and other medical therapies in inflammatory bowel disease. Curr Opin Gastroenterol 11: 321–330

    Article  CAS  Google Scholar 

  • Debinski HS, Kamma MA (1995) Novel drug therapies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 7: 169–181

    PubMed  CAS  Google Scholar 

  • Dullemen HM van, Deventer SJH van, Hommes DW et al. (1995) Treatment of Crohn’s chimeric monoclonal antibody (cA2). Gastroenterology 109: 129–135

    Article  PubMed  Google Scholar 

  • Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326: 107–115

    Article  PubMed  CAS  Google Scholar 

  • Gasché C, Reinisch W, Vogelsang H et al. (1995) Prospective evaluation of Interferon-a in treatment of chronic active Crohn’s disease. Dig Dis Sei 40: 800–804

    Article  Google Scholar 

  • Lerebours E, Bussel A, Modigliani R et al. (1994) Treatment of Crohn’s disease by lymphocyte apheresis: a randomized controlled trial. Gastroenterology 107: 357–361

    PubMed  CAS  Google Scholar 

  • Nordøy A (1991) Is there a rational use for n-3 fatty acids (fish oils) in clinical medicine? Drugs 42: 331–342

    Article  PubMed  Google Scholar 

  • Rubin P, Dube L, Braeckman R (1992) Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by Zileuton, an inhibitor of 5-lipoxygenase. Agents Actions 35: 103–116

    Google Scholar 

  • Sümer N, Palabiyikoglu M (1995) Induction of remission by interferon-α in patients with chronic active ulcerative Colitis. Eur J Gastroenterol Hepatol 7: 597–602

    PubMed  Google Scholar 

  • Weinblatt ME (1995) Methotrexate for chronic diseases in adults. N Engl J Med 332: 330–331

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik, Universität Ulm, Robert-Koch-Str. 8, 89081, Ulm, Germany

    Prof. Dr. Guido Adler

Authors
  1. Prof. Dr. Guido Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Adler, G. (1996). Medikamente und ihre Wirkungsweisen. In: Morbus Crohn - Colitis ulcerosa. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61023-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61023-3_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64661-4

  • Online ISBN: 978-3-642-61023-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation